IL23A and Alzheimer disease: This is supported by clinical trials conducted with risankizumab (an anti-IL-23A Ab) in AD patients aged 12 and older (NCT03706040) (169), as well as with ustekinumab (an anti-IL-12/23p40 Ab) in adult AD patients (NCT01945086), both of which did not demonstrate efficacy.